文献速递帕金森病与运动障碍认知障碍与痴呆

抑郁是帕金森病冲动控制障碍的危险因素

Depression as a Risk Factor for Impulse Control Disorders in Parkinson Disease.
PubMed 文献 · Ann Neurol · 2019-08-31

基于帕金森进展标志物计划(PPMI)队列,纳入基线无冲动控制障碍(ICD)的354例帕金森病患者,前瞻性随访评估基线抑郁对ICD发生的影响。中位随访4.08年,基线抑郁与ICD风险升高相关(HR=1.96,95%CI=1.32-2.9,p<0.001),控制多巴胺受体激动剂使用后风险仍显著(HR=1.97,95%CI=1.33-2.9,p<0.001)。抑郁的帕金森病患者使用多巴胺受体激动剂时ICD风险更高,应谨慎使用。

要点

  • 基线抑郁使帕金森病患者ICD风险约增加一倍(HR=1.96)。
  • 多巴胺受体激动剂独立增加ICD风险(HR=1.87)。
  • 抑郁患者使用多巴胺受体激动剂时ICD风险进一步放大。

核心结论

  • 抑郁 predisposes 帕金森病患者发生冲动控制障碍,且该风险在多巴胺受体激动剂治疗下被放大。

研究设计与样本

  • 基于帕金森进展标志物计划(PPMI)数据,纳入基线无ICD的354例帕金森病患者,前瞻性随访(先每季度、后每半年),中位随访4.08年。

主要发现

  • 354例患者中68例基线抑郁,基线抑郁与ICD风险升高相关(HR=1.96,95%CI=1.32-2.9,p<0.001)。
  • 控制多巴胺受体激动剂使用后抑郁与ICD风险仍显著(HR=1.97,95%CI=1.33-2.9,p<0.001)。
  • 多巴胺受体激动剂独立与ICD发生相关(HR=1.87,95%CI=1.3-2.7,p<0.001)。
  • 抑郁患者接受多巴胺受体激动剂时ICD风险更高;控制多个潜在混杂因素后结果未改变。

临床怎么用

  • 对抑郁的帕金森病患者应谨慎使用多巴胺受体激动剂,并监测冲动控制障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To longitudinally evaluate the role of depression in the development of impulse control disorders (ICDs) in Parkinson disease (PD) patients. METHODS: Using data from the Parkinson's Progression Markers Initiative, we included PD patients without ICDs at baseline according to the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP). Patients were prospectively evaluated first quarterly and then biannually. Development of an ICD was defined as an increase in QUIP scores during follow-up. Using survival proportional hazard models, we studied the effect of baseline depression on ICD risk. We also evaluated this effect controlling for dopamine agonist use as a time-dependent variable and for other potential confounders. RESULTS: Among 354 patients, 68 were depressed at baseline. The median follow-up was 4.08 years. Depression at baseline was associated with higher ICD risk (hazard ratio [HR] = 1.96, 95% confidence interval [CI] = 1.32-2.9, p < 0.001). This risk remained significant after controlling for dopamine agonist use (HR = 1.97, 95% CI = 1.33-2.9, p < 0.001), which was also independently linked to ICD development (HR = 1.87, 95% CI = 1.3-2.7, p < 0.001). Therefore, depressed patients faced an even higher ICD risk when receiving dopamine agonists. Controlling for multiple potential confounders did not alter these results. INTERPRETATION: Depression predisposes to the development of ICDs in PD. This risk is magnified by dopamine agonists. Dopamine agonists should thus be used cautiously in depressed PD patients. ANN NEUROL 2019;86:762-769.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Marín-Lahoz J, Sampedro F, Martinez-Horta S, et al. Depression as a Risk Factor for Impulse Control Disorders in Parkinson Disease. Ann Neurol. 2019. PMID: 31415102. doi:10.1002/ana.25581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。